These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [A study of immunological efficacy of the oral chemical cholera vaccine on experimental animals]. Dzhaparidze MN; Egorova VD; Karaeva LT; Sumarokov AA; Gor'kova Av Zh Mikrobiol Epidemiol Immunobiol; 1976 Nov; (11):115-9. PubMed ID: 1007720 [TBL] [Abstract][Full Text] [Related]
24. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children. Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661 [TBL] [Abstract][Full Text] [Related]
25. Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers. Jertborn M; Svennerholm AM; Holmgren J Vaccine; 1994 Sep; 12(12):1078-82. PubMed ID: 7998416 [TBL] [Abstract][Full Text] [Related]
26. Formulation in tablets of a cholera whole cells inactivated vaccine candidate. Talavera A; Año G; Pino Y; Castaño J; Uribarri E; Riverón L; Gil S; Fernández S; Cedré B; Valmaseda T; Pérez JL; Infante JF; García L; Sierra G Vaccine; 2006 Apr; 24(16):3381-7. PubMed ID: 16460846 [TBL] [Abstract][Full Text] [Related]
27. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804 [TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae. Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542 [TBL] [Abstract][Full Text] [Related]
29. [O-antigen of Vibrio cholerae, serovar Ogawa, Recommended for the production of oral cholera bivalent vaccine]. Dzhaparidze MN; Karaeva LT; Sumarokov AA; Marchuk LM; Nikitina GP Zh Mikrobiol Epidemiol Immunobiol; 1981 Nov; (11):75-81. PubMed ID: 7324656 [No Abstract] [Full Text] [Related]
30. Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine. Peterson JW Infect Immun; 1979 Nov; 26(2):528-33. PubMed ID: 546785 [TBL] [Abstract][Full Text] [Related]
31. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines. Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947 [TBL] [Abstract][Full Text] [Related]
32. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. Cash RA; Music SI; Libonati JP; Craig JP; Pierce NF; Hornick RB J Infect Dis; 1974 Oct; 130(4):325-33. PubMed ID: 4443613 [No Abstract] [Full Text] [Related]
33. Immunity in experimental cholera: effect of parenteral immunization with vaccines and toxoid. Sinha VB; Bhaskaran K Bull World Health Organ; 1973; 49(6):605-13. PubMed ID: 4548387 [TBL] [Abstract][Full Text] [Related]
34. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines. Kollaritsch H; Furer E; Herzog C; Wiedermann G; Que JU; Cryz SJ Infect Immun; 1996 Apr; 64(4):1454-7. PubMed ID: 8606118 [TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers. Chaicumpa W; Chongsa-nguan M; Kalambaheti T; Wilairatana P; Srimanote P; Makakunkijcharoen Y; Looareesuwan S; Sakolvaree Y Vaccine; 1998 Apr; 16(7):678-84. PubMed ID: 9562686 [TBL] [Abstract][Full Text] [Related]
36. Dissecting serotype-specific contributions to live oral cholera vaccine efficacy. Sit B; Fakoya B; Zhang T; Billings G; Waldor MK Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33558237 [TBL] [Abstract][Full Text] [Related]
37. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498 [TBL] [Abstract][Full Text] [Related]
38. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults]. Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092 [TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol™) in adults residing in Lukanga Swamps of Zambia. Ng Ombe H; Simuyandi M; Mwaba J; Luchen CC; Alabi P; Chilyabanyama ON; Mubanga C; Hatyoka LM; Muchimba M; Bosomprah S; Chilengi R; Kwenda G; Chisenga CC PLoS One; 2022; 17(1):e0262239. PubMed ID: 34986195 [TBL] [Abstract][Full Text] [Related]
40. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Cryz SJ; Levine MM; Kaper JB; Fürer E; Althaus B Vaccine; 1990 Dec; 8(6):577-80. PubMed ID: 2087879 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]